Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

Biochimica et biophysica acta - 1 Apr 2009

Nucera Carmelo, Goldfarb Melanie, Hodin Richard, Parangi Sareh

Abstract excerpt

B-Raf(V600E), an oncogenic protein kinase, is the most frequent genetic alteration in papillary thyroid carcinomas (PTC). PTC represents 80-90% of all thyroid cancers and over the past five years, more than 200 manuscripts have been published about the relationship between "B-Raf(V600E) and thyroid cancer". B-Raf(V600E) genetically arises from a transversion point mutation (valine-to-glutamate substitution at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Biopsy, Needle
Share to Isoquinolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Niacinamide

Share to Phenylurea Compounds

Share to Pyridines

Share to Sorafenib

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 19356676
DOI: 10.1016/j.bbcan.2009.01.003
PMCID: PMC3814130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).PMID 19356676Read ↗

BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).Semantic proximity Read ↗

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.Semantic proximity Read ↗

The role of BRAF in the pathogenesis of thyroid carcinoma.Semantic proximity Read ↗

Role of BRAF in thyroid oncogenesis.Semantic proximity Read ↗

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.Semantic proximity Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.Semantic proximity Read ↗

BRAF mutations in thyroid cancer.Semantic proximity Read ↗

The Role of the Kinase Inhibitors in Thyroid CancersSemantic proximity Read ↗

[Advances in the research of BRAF(V600E) gene mutation correlated with papillary thyroid carcinoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.